A series of 53 patients with angiographically proven middle cerebral artery (MCA) trunk occlusions treated with intravenous (in 46) or intra-arterial (in 7) recombinant tissue plasminogen activator (rt-PA) and heparin anticoagulation was studied with serial computed tomography to find out whether recanalization promotes ischemic brain edema and hemorrhagic transformation. Partial or complete recanalization of the MCA trunk was shown in 11 patients immediately after rt-PA treatment by a second angiogram and in altogether 18 patients 1 day later by transcranial Doppler ultrasound or a third angiogram. During follow-up the extent of hypodensity increased in 5 of 18 patients (28%) with reperfusion at 24 h after symptom onset and in 23 of 35 patients (66%) without reperfusion (p < 0.01). The ischemic edema caused a midline shift in 1 of 18 patients (6%) with reperfusion at 24 h after symptom onset, but in 14 of 35 patients (40%) without reperfusion (p < 0.05). Hemorrhagic transformation was associated with reperfusion at 24 h in 7 (39%) patients and occurred in 13 (37%) patients without reperfusion (p > 0.5). Our data suggest that recanalization of MCA trunk occlusion within 24 h after symptom onset does not promote edema or hemorrhagic transformation of ischemic brain tissue.

Keywords:
Cerebral ischemia, Thrombolysis, Middle cerebral artery occlusion, Brain edema, Collaterals
This content is only available via PDF.
© 1993 S. Karger AG, Basel
1993
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.